Suzhou Basecare Medical (HKSE:02170) Quality Rank

View and export this data going back to 2021. Start your Free Trial

What is Suzhou Basecare Medical Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Suzhou Basecare Medical Quality Rank Related Terms

Thank you for viewing the detailed overview of Suzhou Basecare Medical's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Suzhou Basecare Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Suzhou Basecare Medical Corp Ltd (HKSE:02170) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

BioBay, No. 218 Xinghu Street, Unit 101, Building A3, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215000

Website

https://www.basecare.cn

Suzhou Basecare Medical Corp Ltd is engaged in providing genetic testing solutions for assisted human reproduction. The company generates revenues from Sales of testing kits, followed by Sales of testing devices, instruments, and consumables. Basecare focuses on the assisted reproductive sector, such as pre-implantation genetic screening and diagnosis, non-invasive prenatal DNA testing, and chromosome abnormalities testing. Geographically the company generates the majority of its revenue from the PRC.

Executives

Orbimed Capital Llc	2102 Investment manager
Lake Bleu Prime Healthcare Master Fund Limited	2201 Interest of corporation controlled by you
Orbimed Partners Master Fund Limited	2101 Beneficial owner
Dawn Capital Fund	2101 Beneficial owner
Dawn Capital Limited	2102 Investment manager
Hh Spr-xiv Cy Holdings Limited	2201 Interest of corporation controlled by you
Hh Spr-xiv Hk Holdings Limited	2101 Beneficial owner
Hh Spr-xiv Holdings L.p.	2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p.	2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd.	2102 Investment manager